ANDA 209917, held by Teva Pharms USA Inc. Fluticasone Propionate.
As of Nov 16, 2026, ANDA 209917 (Fluticasone Propionate), held by Teva Pharms USA Inc, was first approved by FDA on Nov 3, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 3, 2026 | Original application | Approved | None posted |
| Fluticasone Propionate0.11MG/INH · aerosol, metered;inhalation | Fluticasone Propionate | Rx |
| Fluticasone Propionate0.22MG/INH · aerosol, metered;inhalation | Fluticasone Propionate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters